Want to join the conversation?
In Jan. 2016, $ABBV announced the commencement of a Phase 3 clinical trial program to study the use of its once-daily formulation of ABT-494, its internally developed investigational selective Janus Kinase 1 inhibitor, for the treatment of rheumatoid arthritis. A Phase 2 trial of ABT-494 for the treatment of Crohn's disease is also ongoing.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.